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Summary
TMC-95’s natural cyclic tripeptide metabolites repre-
sent potent competitive proteasome inhibitors. The
constrained conformation of TMC-95 proteasomal in-
hibitors provides the driving force for entropically
high-affinity binding. Based on the crystal structure
of the proteasome:TMC-95A complex, the syntheti-
cally challenging TMC-95 core structure was used for
the design and synthesis of less demanding biphe-
nyl-ether macrocycles, in which the biphenyl-ether
moiety functions as an endocyclic clamp restricting
its tripeptide backbone. These simplified analogs al-
lowed us to identify high plasticity of the proteasomal
tryptic-like specificity pocket. Biphenyl-ether com-
pounds extended with an amide group were hydro-
lyzed by the proteasome, although the crystal struc-
ture of such proteasome:biphenyl-ether complexes
revealed quenching of proteolysis at the acyl-enzyme
intermediate. Our data reveal that biphenyl-ether de-
rivatives bind noncovalently to the proteasomal tryp-
tic-like active site in a reversible substrate-like manner
without allosteric changes of active site residues.
Introduction
Maintaining cellular homeostasis first requires the rec-
ognition and then the disposal of proteins that are of
no further use to the cell [1]. In eukaryotes, the ubiqui-
tin-proteasome pathway serves as the primary molecu-
lar proteolytic machinery for this purpose [2]. The pro-
teolytic core particle of the proteasome (core particle,
CP) is assembled from 28 a- and b-type subunits, which
are arranged in four 7-membered rings that stack upon
each other to yield an a7b7b7a7 complex [3]. The two
outer proteasomal chambers are formed by a and
b rings, whereas the central chamber containing the pro-
teolytically active sites is composed of the two inner
b rings. The most elaborate version of the CP is found
in eukaryotes. Here, a- and b-type subunits have di-
verged into seven different subunits each [4]. Eukaryotic
CPs contain only three proteolytically active b-type sub-
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biochem.mpg.de (L.M.)units, b1, b2, and b5, whereas the remaining subunits are
inactive [5]. The catalytic residues are the N-terminal
threonine residues of the b subunits, in which the hy-
droxyl side chain Thr1Og performs a nucleophilic attack
on the peptide bonds of substrates or on the electro-
philic functional groups of inhibitors, while the free N ter-
minus functions as the proton acceptor [3]. A nucleo-
philic water molecule (NUK) is located in close
proximity to the N-terminal threonine and serves as
a proton shuttle. Additionally, the nucleophilic water
molecule is involved in cleavage of the acyl-ester inter-
mediate, thus regenerating the Thr1Og [5].
Substrate docking occurs in specific channels adja-
cent to the proteolytically active sites, which exhibit
binding sites for short peptides of 9–12 amino acids [6,
7]. Since the likelihood of substrate cleavage depends
on the mean residence time of the peptide at the proteo-
lytically active sites, the observed product cleavage pat-
tern is directly related to the affinity of substrates for the
individual binding clefts [5]. The hydrolytic mechanism
of peptide cleavage in active subunits of eukaryotic
CPs is identical, and active site clefts differ only in their
substrate binding pockets. As a result, each active site
exhibits different cleavage specificities: b1 has cas-
pase-like or postglutamyl peptide hydrolytic (PGPH) ac-
tivity, b2 has tryptic-like (TL) activity, and b5 has chymo-
tryptic-like (CL) activity [8].
Ligand binding to proteasomal b-type subunits has
been extensively studied by analyzing CPs in complex
with various natural and synthetic compounds. Most
synthetic and natural inhibitors of microbial origin inter-
act covalently with all proteasomal proteolytically active
sites by exploiting the high nucleophilicity of the active
site Thr1Og [9, 10]. Nevertheless, affinity of inhibitors
for individual active sites is also dependent on their
characteristic side chain interactions with residues
forming the distinct specificity pockets. For example,
omuralide and salinosporamide A [11, 12] both possess
a reactive b-lactone ring that undergoes ring opening
mediated by the nucleophilic active site Thr1Og, result-
ing in the formation of a stable acyl-ester bond (Fig-
ure 1A) [5, 13]. However, salinosporamide A is recog-
nized by all proteolytically active sites [12], whereas
omuralide shows specificity only for the chymotryptic-
like active site, which exclusively results from the differ-
ent chemical nature of the P1 side chains of the two
inhibitors [11, 12].
Among the natural proteasome inhibitors discovered
so far, only TMC-95A, a complex side chain-bridged tri-
peptide derivative (Figure 1B), blocks all active sites of
CPs in a highly specific and noncovalent manner [14].
The crystal structure of the inhibitor in complex with
yeast CP reveals an optimal fitting of the inhibitor, which
is mostly attributed to the rigidity of the molecule [15].
The constrained conformation provides the driving force
that entropically enhances high-affinity binding. At the
same time, side chains, which are not engaged in the
formation of the macrocycle, fit optimally into the S1
and S3 pockets of the active site cleft [15], thus allowing
the formation of an antiparallel b sheet between the
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608Figure 1. Design of Endocyclic Biphenyl-Ether Compounds Derived from the Natural Product TMC-95
(A) Structural superposition of TMC-95A and omuralide (left panel) and TMC-95A and Ac-Pro-Arg-Leu-Asn-VS (right panel) specifically bound
to subunit b5 and subunit b2, respectively. Carbon atoms of TMC-95A are shown in blue, carbon atoms of omuralide and Ac-Pro-Arg-Leu-Asn-
VS are shown in green, Thr1 is shown in black, and oxygen and nitrogen atoms are drawn in their characteristic color coding. Crystal structures
of related subunits were superimposed by using the program CCP4; inhibitor structures were extracted, and their arrangements were com-
pared. Omuralide and Ac-Pro-Arg-Leu-Asn-VS occupy the S1 and S3 pockets (red dots), respectively, in similar orientation to what has
been observed in TMC-95A.
(B) Chemical structure of the lead component of TMC-95A (left panel) and structurally derived endocyclic oxindole-phenyl compounds (central
panel, synthesized compounds are listed below). The structural data obtained with these TMC-95A analogs were used to create a new struc-
tural element, the endocyclic biphenyl-ether clamp (left panel), colored in green, to restrict the tripeptide derivatives conformationally in 17-
membered macrocycles and thus to preorganize the peptide backbone for high-affinity binding to the proteasomal active site clefts. S1 and S3
specificity sites, illustrated in red, are the major determinants for differential binding of the inhibitors to proteasomal subunits. Synthesized
biphenyl-ether compounds are listed below.
(C) The chemical structures of the macrocyclic biphenyl-ether compounds BIA-1a (left) and BIA-2a (right) as new TMC-95A analogs.inhibitor and residues of the distinct specificity pockets.
The rigidity of TMC-95A and its structural complexity
make the synthesis of this natural product or related de-
rivatives a challenging task [16–18]. Therefore, we have
attempted to apply the concept of rigidity of this uniquemolecular framework to the design of synthetically less
demanding, reversible inhibitors of the proteasome.
In the present study, we succeeded in the design, syn-
thesis, and structural characterization of the selective
and efficient proteasomal inhibitors on the basis of the
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609rigid lead structure of the TMC-95A compound. The in-
hibitors, named BIA-1a/b and BIA-2a/b (Figure 1B),
turned out to be specific for individual proteasomal ac-
tive sites. The structurally complex side chain-bridged
tripeptide derivative of TMC-95A was converted into
a synthetically more feasible molecule by replacing the
rigid oxindole phenyl clamp with a more flexible biphe-
nyl-ether group [19].
Results
Biphenyl-Ether-Bridged Tripeptides as Inhibitors of
the Tryptic-like Active Sites
To create selective TMC-95-based inhibitors that would
specifically bind to one of the three proteolytically active
b-type subunits characteristic P1 and P3 side chain res-
idues have to be introduced. In a first approach, we
designed and synthesized TMC-95 derivatives that con-
tained a stripped-core structure [15], i.e., the phenyl-
oxindole as an endocyclic clamp (Figure 1B) [16, 20].
However, these compounds were difficult to synthesize
and had limited opportunities for side chain modifica-
tions [21]. Additionally, they showed lower inhibitory po-
tency compared to TMC-95A, due to their weaker bind-
ing ability. When we compared the conformational
preferences of these tripeptide derivatives in solution
and in the CP bound state, it became clear that a de-
crease of inhibitory potencies could only derive from
the conformational flexibility of groups mimicking the
P1 and P3 sites [21]. To further test this hypothesis,
we designed less synthetically demanding compounds
carrying a biphenyl-ether clamp of the isodityrosine
type [19], which is known to preorganize the peptide
backbone in a rigidly extended conformation [22–24]
(Figure 1B). To confirm the binding ability and binding
mode of the newly designed inhibitor with TMC-95A,
we replaced the phenyl-oxindole bridge by the biphe-
nyl-ether clamp (BIA-1a/b), thus keeping the N-propyl
group and L-asparagine as P1 and P3 residues, respec-
tively (Figure 1C). Compared to the identical tripeptide
derivative with the phenyl-oxindole bridge, the biphe-
nyl-ether bridge lowers inhibition of both chymotryptic-
as well as tryptic-like activities by a factor ofw2 [19]. In
order to characterize the origin of the lower binding po-
tency of BIA-1a/b compared to their TMC-95 analogs,
we determined the crystal structure of BIA-1a and BIA-
1b in complex with the yeast CP.
X-Ray Structures of Yeast CP Complexed
with BIA-1a and BIA-1b
The crystal structure analysis of the yeast CP:BIA-1a
complex revealed clear electron density for the inhibitor
molecule (Figure 2A). In the structure, the peptide back-
bone of BIA-1a adopts a b conformation and aligns with
the short b strand of the active site cleft, thus forming an
antiparallel b sheet structure, similar to what has been
observed for TMC-95A. As expected and according to
the binding mode of TMC-95A, BIA-1a does not cova-
lently interact with the active site nucleophilic threonine
residue and follows the typical reversible binding mech-
anism of TMC-95 (Figure 2C). Surprisingly, the crystallo-
graphic data identified BIA-1a bound only to the tryptic-
like active sites of the proteasome, whereas TMC-95
molecules were found to bind to all active centers. In or-der to further characterize this unique and selective
binding behavior of BIA-1a, we performed kinetic mea-
surements. Since the 4-nitro substituent of BIA-1a acts
as a quencher, thus hampering kinetic measurements,
we reduced the 4-nitro group to a 4-amino group, result-
ing in compound BIA-1b (Figure 1B). Interestingly, the
kinetic data revealed that BIA-1b blocks both the tryp-
tic- and chymotryptic-like activity. Therefore, we deter-
mined the crystal structure of BIA-1b in complex with
the yeast 20S proteasome as well. The structural data
show that both BIA-1a and BIA-1b only bind to the tryp-
tic-like active site, hence contradicting our kinetic data
(see Discussion). The structural superposition of BIA-
1a and BIA-1b in their bound forms indicates analogous
conformations of even the 4-nitro and 4-amino groups,
respectively (data not shown). However, the unique ac-
tive site specificity of BIA-1a/b compared to TMC-95A
can be explained by the structural superposition of
BIA-1a and TMC-95A bound to the tryptic-like active
site, revealing striking differences in the binding mode
of the biphenyl-ether and phenyl-oxindole side chain-
bridged macrocycles (Figure 3B): although BIA-1a/b
and TMC-95A show a high degree of conservation in
their constrained geometry, conformation, and binding
mode, TMC-95A is additionally hydrogen bridged by
the CO of the oxindole to the NH of Gly23 (Figure 3B)
[15]. Since this functional group is absent in the endocy-
clic biphenyl-ether of BIA-1a/b, their extended b-type
backbone conformation is destabilized as compared
to TMC-95A. Thus, the high selectivity of BIA-1a/b com-
pounds is explained by their strong interactions with
residues exclusively found in the tryptic-like active site
(see below). Furthermore, the conformation of BIA-1a
in solution, as determined by NMR [19], does not change
in a detectable manner upon its binding to the active site
of the proteasome. This confirms the efficiency of the
endocyclic biphenyl-ether clamp in conformational pre-
organization of the peptide backbone. According to Bo-
ger et al., the synthesis of the biaryl-ether moiety pro-
duces two atropoisomers that differ in the orientation
of the two phenyl rings [25]. We are aware that our syn-
thesis could have resulted in a mixture of both atro-
poisomers; however, we were only able to detect one
isomer in the crystal structure. Our conclusion is that
the proteasome preferentially binds one of the two atro-
poisomers from the mixture.
Plasticity of the Proteasomal Active Sites
Most structural data available on selective ligand bind-
ing to proteins particularly focus on adaptation and
movement of the ligand. However, the flexibility of pro-
tein residues and their concerted movements upon li-
gand binding are just as crucial for stabilizing the ligand
bound state and have significant effects on IC50 values.
In proteasomes, structural rearrangement of side chain
residues, in particular those forming the S1 specificity
pocket, has been confirmed so far only for subunit b5
[5]. Here, we identified that binding of BIA-1a/b to sub-
unit b2 generates substantial structural rearrangement
of residues that are not primarily involved in the forma-
tion of the S3 pocket (Figure 3A). This observation is sur-
prising, since structural superposition of TMC-95A and
BIA-1a/b in their bound forms shows that their con-
strained geometry, conformation, and binding mode
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610Figure 2. Structural Binding Mode of Endocyclic Biphenyl-Ether Compounds
(A and B) Stereorepresentation of the tryptic-like active site of the yeast 20S proteasome in complex with (A) BIA-1a and (B) BIA-2a. The back-
bone of proteasomal subunits b2 and b3 are colored in lavender and pink, respectively, and are shown as coils; the ligands are represented as
ball-and-stick models. The carbonyl atoms of BIA-1a and BIA-2a are colored in green. Electron density maps (colored in gray) are contoured
from 1s in similar orientations around Thr1 (colored in black) with 2Fo 2 Fc coefficients after 2-fold averaging. Apart from the bound inhibitor
molecules, structural rearrangements were only noted in the specificity pockets. Gln22 of subunit b2, colored in black, performs substantial
structural rearrangements and stabilizes the biphenyl-ether ligands by four specific hydrogen bonds, indicated as brown, dashed lines.
Covalent linkage of BIA-2a to the active site Thr1Og of subunit b2 is drawn in magenta.
(C and D) Stereorepresentations of the structural superpositions of (C) BIA-1a and TMC-95A and (D) BIA-1a and BIA-2b. Ligands are oriented
and colored in a similar manner as shown in Figure 1A, except carbon atoms, which are depicted in green for BIA-1a, in salmon for TMC-95A,
and in yellow for BIA-2a. (C) Note the structurally conserved b conformation in all ligands and the high structural similarities between the en-
docyclic oxindole-phenyl clamp of TMC-95A and the endocyclic biphenyl-ether clamp in BIA-1a, (D) but the different orientation of the biphe-
nyl-ether clamp between BIA-1a and BIA-2a.are very much alike (Figure 2C). As already discussed,
the biggest difference is that the endocyclic biphenyl-
ether lacks the functional oxindole group present inthe TMC-95A complex structure, thus destabilizing the
extended b-type backbone conformation of the inhibi-
tor. However, in contrast to the CP:TMC-95A complex
Peptide Splicing Activities of the Proteasome
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(A and B) Surface representation (upper panel) of (A) TMC-95A and (B) BIA-1a bound to the proteasomal tryptic-like active site (colored in
green). Thr1, shown in white, is not linked to these ligands. Surface colors indicate positive and negative electrostatic potentials contoured
from 15kT/e (intense blue) to 215kT/e (intense red). The plasticity of the tryptic-like active site between TMC-95A and BIA-1a binding is high-
lighted in white. The arrow indicates ligand-specific structural rearrangements involving Gln22 of subunit b2. Lower panel: (A) Schematic over-
view of bound TMC-95A and (B) BIA-1a. Hydrogen bonds with their correlated distances in A˚ngstroms are illustrated as pink, broken lines.
Characteristic oxygen and nitrogen atoms are drawn in their characteristic color coding. Residues from subunit b3 that are involved in specific
TMC-95A interactions are shown in gray. TMC-95A is additionally hydrogen bridged by the CO of the oxindole to the NH of Gly23, depicted in
yellow. Since this functional group is absent in the endocyclic biphenyl-ether of BIA-1a/b, their extended b-type backbone conformation is
destabilized as compared to TMC-95A. The high selectivity of BIA-1a/b compounds is explained by their strong interactions with Gln22
exclusively found in the tryptic-like active site (colored in yellow).structure, binding of the endocyclic biphenyl-ether
group can only be stabilized at the tryptic-like active
site by four additional hydrogen bonds with Gln22 of
subunit b2 (Figure 3). To summarize, despite high struc-
tural similarities between BIA-1a/b and the natural lead
compound TMC-95A, our observations confirm that
the endocyclic biphenyl-ether clamp of BIA-1a/b is not
involved in hydrogen bonding, but plays an important
role in entropically establishing high-affinity binding.
High-Affinity Biphenyl-Ether-Based Substrates
for the Tryptic-like Active Site
The structural information derived from the CP:BIA-1a/b
complexes provided the basis for the design of a b2-
selective substrate that targets the inhibition of the tryp-
tic-like activity in a mechanism-based fashion. In a previ-
ous study [26, 27], selective deactivation of subunit b2
was achieved by treatment with the synthetic peptidyl-vinylsulfone Ac-PRLN-VS, while Ac-YLLN-VS showed
nonspecific binding to all active centers. The conclusion
of this study was that substrate selectivity is dependent
on the S1 as well as the S3 pocket. Taking into account
also the complementarity of the S1 pocket of the b2 sub-
unit with basic residues, a new modified endocyclic bi-
phenyl-ether compound with L-arginine side chains in
both the P1 and P3 pockets (Figure 1C) has been de-
signed and synthesized. The P1-arginine side chain of
the compound was extended by an amide group to
achieve close contact with Thr1Og (BIA-2a/b, Figure 1C).
In contradiction to kinetic measurements and similar to
what has been observed for BIA-1a/b, the crystal struc-
ture of the CP:BIA-2a/b complexes revealed that the
compounds bind solely to the tryptic-like active center
and form a covalent acyl-ester bond with the active site
Thr1Og (Figure 2B). The crystallographic data sup-
port the formation of the acyl-enzyme intermediate
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612during the first step of amide hydrolysis. Indeed, mass
spectrometric analysis of the medium after incubation
of yeast CP with BIA-2a/b confirmed hydrolysis of the
C-terminal amide within 2 hr at room temperature.
Thus, our findings confirm that the proteasomal proteo-
lytically active sites maintain their functional efficiency
upon binding of the substrate-like inhibitor BIA-2a. The
overall binding mode of BIA-2a and BIA-2b is similar to
that of the BIA-1a/b compounds, with almost identical
backbone geometry (Figure 2D). Therefore, TMC-95A
and its biphenyl-ether derivatives bind to the proteaso-
mal active sites noncovalently in a reversible sub-
strate-like manner, causing no allosteric changes of the
active site residues.
Structural superposition of noncovalently and cova-
lently bound inhibitors of the proteasome revealed that
their backbone geometry upon binding to the active
sites is similar, showing that all inhibitors bind to the pro-
teasome in a substrate-like manner. Corresponding to
our findings, the small, irreversible inhibitors lactacystin
and salinosporamide A both form an ester bond with the
Thr1Og [5, 13]. The slow rate of hydrolysis of these inhib-
itors can be explained by the out-of-place position of the
NUK water molecule. We could not confirm this theory
with the crystal structure of the CP:BIA-2a/b complexes,
since it has not been possible to localize the nucleophilic
water molecule due to insufficient electron density. Nev-
ertheless, the clear identification of the ester bond as an
intermediate step of amide hydrolysis of BIA-2a con-
firms that the extended half-life of the acyl-enzyme inter-
mediate formed by the proteasome and the tight binding
substrates could well suffice for rates of aminolysis that
compete with hydrolysis. To analyze whether such re-
versed proteolysis can generally occur in the cavity of
CPs, the yeast proteasome was incubated with BIA-2a
and an excess of H-Ala-Gly-OH. However, mass spec-
trometric analysis of the incubation medium failed to de-
tect any spliced BIA-2a species C-terminally extended
by the dipeptide amide. These results are in agreement
with experiments, showing that proteasomal degrada-
tion products possess only substrate-specific cleavage
patterns [7]. This confirms experiments reported by Vi-
gneron et al. [28], who found that exclusively specific
peptides, not a random library of peptides, can be syn-
thesized by the proteasome from fragments present in
the proteasomal cavity after degradation of proteins.
Thus, we suggest that, for aminolysis, the reacting pep-
tide also has to be tightly bound to the thus far structur-
ally unidentified primed sites of the distinct proteasomal
active centers.
Discussion
The use of structural frameworks of natural compounds
as leads for the design of synthetically more feasible,
bioactive small molecules has developed over the last
years into an efficient concept. This strategy allowed
us, in the case of TMC-95A (so far the only reversible
proteasome inhibitor of natural origin), to create struc-
turally simplified, biphenyl-ether-bridged tripeptide de-
rivatives, followed by their modified tripeptide analogs,
which are side chain crossbridged by an endocyclic bi-
phenyl-ether clamp. The tripeptides can be readily as-
sembled as linear precursors that are then crossbridgedwith efficient chemistries [29, 30]. This approach re-
sulted in the preparation of BIA-1a/b and BIA-2a/b pro-
teasomal inhibitors via a series of biphenyl-ether com-
pounds. The final compounds take advantage of the
entropic contribution of the structurally preorganized,
rigid framework of TMC-95A, which has defined back-
bone architecture and geometry and carries additionally
suitable side chains for binding to the crucial S1 and S3
pockets. Treatment of the yeast proteasome with BIA-
2a/b allowed us to detect and structurally characterize
an acyl-enzyme intermediate that might serve as an
acyl donor whenever high-affinity substrate fragments
reside at the primed sites for a sufficiently long time.
Thus, the extended lifetime of the acyl-enzyme interme-
diate would allow a nucleophilic attack by a peptide
amino terminus onto the acyl ester intermediate instead
of the NUK-mediated hydrolysis of the intermediate,
generating spliced peptide fragments, as previously
has been observed [28].
Crystallographic data can only provide an average
snapshot of a defined state of the enzyme, and impor-
tant parameters such as IC50 values and kinetics of the
enzymatic reaction cannot be predicted solely based
on structures. In most cases, crystallographic data are
in accord with determined IC50 values. However, in pro-
teasomes the rate-limiting step of proteolysis is sub-
strate accessibility. Furthermore, proteolytic activity as-
says are generally performed with small fluorogenic
substrates, which proteasomes can only poorly de-
grade. This explains why in vitro activity assays on pro-
teasomes depend significantly on buffer conditions and
substrate mimetics. As observed in the present study
with BIA-1 and BIA-2 compounds, the proteasomal
structural and enzymatic activity experiments are in
contradiction. Similar controversial findings between
crystallographic data and enzyme kinetics were also re-
ported for irreversible inhibitors such as lactacystin [11]
and calpain inhibitor-I [5, 31].
The X-ray data analyzed in this study provided us with
insights for improvement of the binding affinity of BIA-
2a/b-type molecules by modifications in the S10 binding
sites. Our previous attempts to reach the primed sub-
sites of the proteasomal active centers with C-terminally
extended TMC-95A-like molecules were unsuccessful,
and X-ray analysis of this type of molecule complexed
with yeast CP clearly revealed structural origins of this
failure [21]. Conversely, the tripeptides with the biphe-
nyl-ether clamp bind to proteasomal active centers as
perfect substrate mimetics, thus allowing for a more ra-
tional extension into the S0 active site cleft. Indeed, incu-
bation of a BIA-2a derivative carrying the Ala-Gly-NH2
group in place of the C-terminal amide with yeast 20S
proteasome led to quantitative hydrolysis of the Arg-
Gly peptide bond as confirmed by mass spectrometry.
This observation opened the possibility of constructing
inhibitor molecules that protrude into the S0 sites via non-
scissile isosteric peptide bond replacements. Although
some information about this site of the active centers
has already been gathered from experiments with homo-
belactosin C [32], the new constructs are expected to
provide more detailed insight into the structural charac-
teristics of this part of the proteasomal active centers, as
well as open perspectives for improving binding affini-
ties of proteasomal ligands. To summarize, the present
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613study underlines the importance of confirming functional
experimental results with structural analysis in experi-
ments with ligands, designed on the basis of natural
compound lead structures.
Significance
The proteasome is responsible for the degradation of
ubiquitin-marked proteins. Structurally highly homol-
ogous ‘‘immuno’’ proteasomes additionally perform
efficient generation of antigenic peptides. Recently, it
has been reported that the proteasome is also able to
produce noncontiguous antigenic peptides via a splic-
ing mechanism, which contributes to the great struc-
tural diversity of generated peptides [28]. Reversed
proteolysis by the proteasome can only be explained
by creation of a stabilized acyl-enzyme intermediate
at the active center, which leads to aminolysis of
a bound peptide instead of the usual hydrolysis by
the nucleophilic water molecule (NUK). TMC-95A, the
only natural reversible proteasome inhibitor, binds to
the nonprimed sites of the active centers with high af-
finity [15]. We took advantage of the rigid structural
framework of this molecule with the conformationally
restricted tripeptide backbone and designed less syn-
thetically complex macrocycle molecules. The next
step was to introduce the biaryl-ether as an endocyclic
clamp in order to restrict the tripeptide backbone.
Their derivatives with an extended amide group in
the P1 site were shown to undergo slow hydrolysis in
solution in a substrate-like manner. In crystals, how-
ever, we observed quenching of proteolysis at the
acyl-enzyme intermediate step, which explains the
surprisingly high resistance of tightly binding sub-
strates toward hydrolysis. We propose that substrates
that remain at the active centers as acyl-enzyme inter-
mediates for a sufficiently long time would also allow
aminolysis by the N termini of proteolytic fragments
tightly bound to the proteasomal primed site.
Experimental Procedures
Synthesis
Compounds BIA-1a, BIA-2a, and the C-terminally extended BIA-3a
were prepared by essentially following the procedures reported in
our previous communication [19]. (S)-3-Fluoro-4-nitrophenylalanine
was prepared according to Vergne et al. [33] by using acetylation of
the racemic amino acid analog with subsequent enantiomeric reso-
lution by acylase I from Asperigillus melleus. It was then applied as
an N-benzyloxycarbonyl derivative for the synthesis of the linear
precursors Z-Phe(3-F,4-NO2)-Asn-Tyr-NH-CH2CH2CH3 and Z-
Phe(3-F,4-NO2)-Arg(Pbf)-Tyr-Arg(Pbf)-NH2 in solution, while Z-
Phe(3-F,4-NO2)-Arg(Pbf)-Tyr-Arg(Pbf)-Ala-Gly-NH2 was synthe-
sized on Sieber amide resin and cleaved with 1% TFA in CH2Cl2 (5
min). Macrocyclization was carried out by the method of Boger
et al. [29], which allowed for better yields than the method of Beugel-
mans [30] used in our previous syntheses [19]. Quantitative reduc-
tion of the nitro-derivatives was achieved by hydrogenation over
Raney-Nickel. Details of the syntheses are reported in the Supple-
mental Data (available with this article online).
Kinetic Assays
Kinetic assays were carried out as reported previously [19].
Cocrystallization
Crystals of the 20S proteasome from S. cerevisiae were grown in
hanging drops at 24ºC as already described [34]. Crystals were incu-bated for 60 min with compounds BIA-1a and BIA-2a and were dif-
fracted to 3.0 A˚ and 2.8 A˚, respectively. X-ray intensities were eval-
uated by using the MOSFILM program package (version 6.1), and
data reduction was performed with CCP4 [35]. The anisotropy of dif-
fraction was corrected by an overall anisotropic temperature factor
by comparing observed and calculated structure amplitudes by us-
ing the program CNS [36]. Electron density was improved by averag-
ing and back transforming the reflections ten times over the 2-fold
noncrystallographic symmetry axis by using the program package
MAIN [37]. Conventional crystallographic rigid body, positional,
and temperature factor refinements were carried out with CNS [36]
by using the yeast 20S proteasome structure as a starting model
[5]. For model building, the program MAIN was used. Modeling ex-
periments were performed by using the coordinates of the yeast
20S proteasome [5] with the program MAIN [37]. For BIA-1a, the re-
fined coordinates revealed Rcrys = 21.7%, Rfree = 24.1%, rms bond
deviations of 0.007 A˚, and rms angles of 1.3º. For BIA-2b, the refined
coordinates revealed Rcrys = 20.1%, Rfree = 23.6%, rms bond devia-
tions of 0.007 A˚, and rms angles of 1.3º. Coordinates have been de-
posited with the Protein Data Bank, Brookhaven, NY, under acces-
sion number 2GPL. X-ray data and refinement statistics are
available as Supplemental Data.
Supplemental Data
Supplemental Data include the synthesis and analytical character-
ization of the biphenyl-ether compounds, additional details of the ki-
netic assays, and X-ray analysis and are available at http://www.
chembiol.com/cgi/content/full/13/6/607/DC1/.
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